LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

ConferencepositiveLEQEMBIPositive

AI Analysis

Summary

Eisai and Biogen presented real-world LEADER study results at AAIC 2026 showing LEQEMBI maintained stability in over 75% of early Alzheimer's patients with nearly 7% improvement over 17 months of treatment. The findings support long-term benefits of continuous LEQEMBI treatment outside clinical trial settings.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Real-world study showed over 75% of early Alzheimer's patients remained stable and nearly 7% improved over average of 17 months of treatment

Importance:6/10

Sentiment:

0.75

LEQEMBIAlzheimer's DiseaseReal-world EvidenceAAIC 2026Clinical DataTreatment Stability

Related Companies

$ESALY $BIIB

Read the original article

Published by PR Newswire Biotech on July 14, 2026 3:15 PM

Read Original